Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AMSBIO Expands U.S. Operations

By Drug Discovery Trends Editor | April 23, 2014

AMSBIO has announced the opening of a new North American headquarters with executive management facilities in Cambridge, Mass., for its U.S. subsidiary, AMSBIO LLC.
 
Commenting on this strategic move, Alex Sim, president, AMSBIO, said “The U.S. is the single largest market for our stem cell and regenerative medicine, glycobiology enzymes/substrates and tissue derived products. Drawing upon upon our in-depth expertise in extracellular matrices we are able to also provide elegant solutions for studying cell motility, migration, invasion and proliferation.”  He added, “Our North American customer base has been growing strongly over recent years. From the new East Coast facility we will provide local informed service and support as well as next day delivery of a comprehensive range of enabling technology products to help improve the productivity of our U.S. customers.”
 
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance physiologically relevant screening outcomes and subsequently reduce drug development attrition rates. AMSBIO serves the European market from facilities in Switzerland, Germany, and the UK. This latter location provides the logistics and distribution services as well as housing a multi lingual marketing and technical staff made up of scientists with many years of experience in cutting edge technology. 
 
Date: April 22, 2014
Source: AMSBIO

Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE